12 Results for "

ferroptosis resistance

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "ferroptosis resistance" in MCE Product Catalog:

1
1 Cited Publications
製品番号: HY-N0910
CAS 番号: 155683-00-4
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 + T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca 2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .
loading...
    loading...
1
1 Cited Publications
製品番号: HY-153190
CAS 番号: 2740522-79-4
純度:  99.25%
研究分野:  

Cancer

W1131 is a potent STAT3 inhibitor, triggering ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including IL6-JAK-STAT3 pathway and ferroptosis pathway .
loading...
    loading...
製品番号: HY-144439
CAS 番号: 118666-03-8
純度:  99.94%
HTS07545 is a sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC50 of 30 nM. HTS07545 inhibits SQOR function and mediates resistance to ferroptosis. HTS07545 reduces tumor volume and weight of pancreatic ductal adenocarcinoma. HTS07545 induces tumor cell nuclear necrosis. The combination of HTS07545 and Erastin (HY-15763) exerts a synergistic effect without causing significant weight loss in mice. HTS07545 can be used in studies related to pancreatic ductal adenocarcinoma and heart failure [1] [2].
loading...
    loading...
製品番号: HY-110067
CAS 番号: 675848-25-6
VO-OHPic is a reversible, noncompetitive PTEN inhibitor with an human IC50 value of 46 nM. VO-OHPic inhibits PTEN signaling, activates Akt-GSK3β and Nrf-2/HO-1 pathways, induces apoptosis resistance and elevates IL-10 levels. VO-OHPic inhibits autophagy, ferroptosis and oxidative stress. VO-OHPic can be used for the research of acute myocardial infarction, intervertebral disc degeneration, cardiomyopathy and cancer .
loading...
    loading...
製品番号: HY-175633
ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor with a -ferrocenophane group (IC50 of 3.4 μM). ML210-ansaFc potently induces ferroptosis by increasing the level of ROSand promoting lipid peroxidation (LPO) in cancers cells. ML210-ansaFc has an anticancer activity and suppresses tumor growth in tumor 3D spheroids. ML210-ansaFc can be used for cancer therapy resistance research .
loading...
    loading...
製品番号: HY-106159
CAS 番号: 186348-05-0
SB-T-101141 is a novel taxane. SB-T-101141 effectively induces a noncanonical ferroptosis to overcome Paclitaxel (HY-B0015) resistance of breast cancer. SB-T-101141 facilitates the production of iron and ferrous ions and ROS. SB-T-101141 stably binds to KHSRP to inhibit the iron-dependent expression of CISD1 related to iron homeostasis. SB-T-101141 synergistically enhances the iron-dependent activation of JNK and PERK pathways via KHSRP. SB-T-101141 suppresses breast tumor growth in MCF-7(PR)/MDA-MB-231(PR) or KHSRP knock-down MCF-7 xenograft mice model .
loading...
    loading...
製品番号: HY-161647
Antitumor agent-156 (Compound 20) causes DNA damage and mitochondrial dysfunction, promotes reactive oxygen species generation, activates endoplasmic reticulum stress, and induce apoptosis, autophagy and ferroptosis. Antitumor agent-156 shows superior antitumor activity against cancer cells including Cisplatin (HY-17394) resistance cells. Antitumor agent-156 displayS good liver-targeting ability .
loading...
    loading...
製品番号: HY-176719
CAS 番号: 2632263-80-8
AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is an AKR1B1/STAT3/SLC7A11 regulator that reverses DOX resistance in MCF-7/ADR cells by enhancing ferroptosis activity. AKR1B1/STAT3/SLC7A11-regulator-1 can be used in breast cancer research .
loading...
    loading...
製品番号: HY-W342441
CAS 番号: 54827-14-4
Monosialoganglioside GM3 (bovine) is a monosialoganglioside and an inhibitor of VEGFR2 and Akt. At a concentration of 20 μM, Monosialoganglioside GM3 inhibits angiogenesis and reduces the proliferation and migration of human umbilical vein endothelial cells (HUVECs) by inhibiting VEGFR2 and Akt phosphorylation. Ganglioside GM3 also inhibits ferroptosis, providing protective effects during the formation of abdominal aortic aneurysms. Additionally, Monosialoganglioside GM3 (bovine) acts as an inhibitor of insulin signaling, inducing the dissociation of the insulin receptor (IR)-Caveolin-1 complex from lipid microdomains and causing insulin resistance in adipocytes. Monosialoganglioside GM3 (bovine) can be used in cancer and metabolic disease research .
loading...
    loading...
製品番号: HY-182067
anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer .
loading...
    loading...
製品番号: HY-15772G
CAS 番号: 1421373-65-0
別名: AZD-9291 (GMP); Mereletinib (GMP)
Osimertinib (AZD-9291; Mereletinib) GMP is the GMP level of Osimertinib (HY-15772). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP is an inhibitor that selectively targets EGFR T790M and activated EGFR mutants. Osimertinib GMP exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP can be used in research related to radioresistant glioblastoma and non-small cell lung cancer .
loading...
    loading...
製品番号: HY-15772GL
CAS 番号: 1421373-65-0
別名: AZD-9291 (GMP Like); Mereletinib (GMP Like)
Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFR T790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer .
loading...
    loading...
  • 1